State of Wisconsin Investment Board Sells 121,065 Shares of Eli Lilly and Company (NYSE:LLY)

State of Wisconsin Investment Board decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 11.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 898,424 shares of the company’s stock after selling 121,065 shares during the period. State of Wisconsin Investment Board’s holdings in Eli Lilly and Company were worth $75,566,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Holderness Investments Co. acquired a new position in Eli Lilly and Company during the first quarter worth approximately $228,000. Financial Advisory Service Inc. boosted its position in Eli Lilly and Company by 1.7% in the first quarter. Financial Advisory Service Inc. now owns 6,084 shares of the company’s stock worth $512,000 after buying an additional 103 shares in the last quarter. State of Tennessee Treasury Department boosted its position in Eli Lilly and Company by 13.3% in the first quarter. State of Tennessee Treasury Department now owns 1,222,822 shares of the company’s stock worth $102,852,000 after buying an additional 143,357 shares in the last quarter. Jaffetilchin Investment Partners LLC acquired a new position in Eli Lilly and Company during the first quarter worth approximately $667,000. Finally, Fairfield Bush & CO. boosted its position in Eli Lilly and Company by 0.8% in the first quarter. Fairfield Bush & CO. now owns 24,713 shares of the company’s stock worth $2,079,000 after buying an additional 200 shares in the last quarter. 75.49% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Eli Lilly and Company (NYSE LLY) opened at 82.29 on Monday. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72. The firm’s 50-day moving average price is $80.49 and its 200-day moving average price is $79.95. The stock has a market cap of $86.92 billion, a price-to-earnings ratio of 39.79 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 25th. The company reported $0.98 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.96 by $0.02. The business had revenue of $5.23 billion during the quarter, compared to the consensus estimate of $5.22 billion. Eli Lilly and Company had a net margin of 10.13% and a return on equity of 26.64%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.83 earnings per share. On average, analysts forecast that Eli Lilly and Company will post $4.12 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Eli Lilly and Company’s dividend payout ratio (DPR) is 100.48%.

COPYRIGHT VIOLATION NOTICE: This story was reported by WKRB News and is owned by of WKRB News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.wkrb13.com/markets/2284320/state-of-wisconsin-investment-board-sells-121065-shares-of-eli-lilly-and-company-nyselly.html.

A number of research analysts have recently commented on the company. Citigroup Inc. reaffirmed a “buy” rating and set a $100.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, July 4th. Barclays PLC upped their target price on Eli Lilly and Company from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. Zacks Investment Research cut Eli Lilly and Company from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th. Jefferies Group LLC reaffirmed a “buy” rating and set a $93.00 target price on shares of Eli Lilly and Company in a research note on Thursday, June 22nd. Finally, BidaskClub raised Eli Lilly and Company from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $87.65.

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $84.43, for a total value of $17,730,300.00. Following the completion of the transaction, the insider now owns 124,265,804 shares in the company, valued at $10,491,761,831.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Enrique A. Conterno sold 25,000 shares of the business’s stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the completion of the transaction, the senior vice president now owns 114,217 shares of the company’s stock, valued at approximately $9,452,598.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 474,733 shares of company stock valued at $39,634,487. Insiders own 0.20% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284320/state-of-wisconsin-investment-board-sells-121065-shares-of-eli-lilly-and-company-nyselly.html

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.